Mineralys Therapeutics, Inc.

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a biopharmaceutical company dedicated to developing targeted treatments for cardio-renal-metabolic diseases. Their scientific focus is on the critical role of aldosterone in these conditions, aiming to improve outcomes for individuals managing hypertension, chronic kidney disease (CKD), and related disorders. The company is advancing Lorundrostat, a therapeutic in its pipeline, to address dysregulated aldosterone as a driver of these serious health challenges. By leveraging evolving scientific insights, Mineralys Therapeutics is committed to bringing innovative solutions to patients, addressing unmet needs in cardiovascular and metabolic health.